An investigation on the effects of Afrocentric missense variations on the structure and function of CYP2A6 protein
- Authors: Makombe, Chipo Perpetual
- Date: 2025-04-02
- Subjects: Missense mutation , Structural dynamics , Enzyme activity , Drugs Metabolism , CYP2A6
- Language: English
- Type: Academic theses , Master's theses , text
- Identifier: http://hdl.handle.net/10962/479119 , vital:78262
- Description: Pharmacogenomics, the foundation of personalized medicine distinguishes patients into different categories based on their response to the risk of a disease. Cytochrome P450 (CYPs) proteins are a family of enzymes critical in the metabolism of drugs and other substances. Genetic polymorphisms in CYPs can result in different enzymatic activity in individuals influencing the efficacy and toxicity of drugs. One of the CYPs which primarily metabolizes nicotine and other pharmaceutical drugs such as Artemisinin and Artesunate, Pilocarpine, Valproic Acid and Letrozole is CYP2A6. The gene encoding the protein is highly polymorphic and this can affect the rate of metabolism of drugs in individuals. Previously most studies unveiled connections between CYP2A6 variants and nicotine. Implications concerning the effects of specific missense variations in CYP2A6 drug metabolism have deficiencies. This study aimed to critically examine the structural and functional implications of 13 CYP2A6 allele variations on CYP2A6 protein using Bioinformatics techniques. Methods used were template selection, mutagenesis, parameter assignment and protonation. Molecular Dynamics to get insights regarding protein behavior at an atomic level, clustering to identify conformations during a simulation and DSSP for secondary structure analysis to monitor how secondary structures evolve. Berendsen and Parinello-Rahman barostats at production run were used for comparison. A global analysis was conducted to identify structural transitions (RMSD, RMSF, and Rg), clustering, and secondary structure prediction. Results from Berendsen barostat were inconsistent compared to Parrinello-Rahman barostat implying that CYP2A6 is sensitive to the pressure coupling parameter for precise and accurate results. Our clustering results showed each system in one conformation, fluctuations and shifts on the C-D, H-I loops and F, G, and L helices on variants I149M, F118l, K476R, and E390K_N418D_E419D. This indicated a potential loss of function limiting the protein’s ability to conformational flexibility for catalysis and substrate recognition. Certain regions of CYP2A6 became more rigid due to variations, which could have a negative impact on the catalytic activity, regulatory interactions, and general function of the enzyme in metabolism. Globally the variations did not cause large changes to the protein, there is need for a local analysis using Dynamic Residue Networks to study how residue interactions affect the function of CYP2A6. , Thesis (MSc) -- Faculty of Science, Biochemistry, Microbiology and Bioinformatics, 2025
- Full Text:
- Date Issued: 2025-04-02
- Authors: Makombe, Chipo Perpetual
- Date: 2025-04-02
- Subjects: Missense mutation , Structural dynamics , Enzyme activity , Drugs Metabolism , CYP2A6
- Language: English
- Type: Academic theses , Master's theses , text
- Identifier: http://hdl.handle.net/10962/479119 , vital:78262
- Description: Pharmacogenomics, the foundation of personalized medicine distinguishes patients into different categories based on their response to the risk of a disease. Cytochrome P450 (CYPs) proteins are a family of enzymes critical in the metabolism of drugs and other substances. Genetic polymorphisms in CYPs can result in different enzymatic activity in individuals influencing the efficacy and toxicity of drugs. One of the CYPs which primarily metabolizes nicotine and other pharmaceutical drugs such as Artemisinin and Artesunate, Pilocarpine, Valproic Acid and Letrozole is CYP2A6. The gene encoding the protein is highly polymorphic and this can affect the rate of metabolism of drugs in individuals. Previously most studies unveiled connections between CYP2A6 variants and nicotine. Implications concerning the effects of specific missense variations in CYP2A6 drug metabolism have deficiencies. This study aimed to critically examine the structural and functional implications of 13 CYP2A6 allele variations on CYP2A6 protein using Bioinformatics techniques. Methods used were template selection, mutagenesis, parameter assignment and protonation. Molecular Dynamics to get insights regarding protein behavior at an atomic level, clustering to identify conformations during a simulation and DSSP for secondary structure analysis to monitor how secondary structures evolve. Berendsen and Parinello-Rahman barostats at production run were used for comparison. A global analysis was conducted to identify structural transitions (RMSD, RMSF, and Rg), clustering, and secondary structure prediction. Results from Berendsen barostat were inconsistent compared to Parrinello-Rahman barostat implying that CYP2A6 is sensitive to the pressure coupling parameter for precise and accurate results. Our clustering results showed each system in one conformation, fluctuations and shifts on the C-D, H-I loops and F, G, and L helices on variants I149M, F118l, K476R, and E390K_N418D_E419D. This indicated a potential loss of function limiting the protein’s ability to conformational flexibility for catalysis and substrate recognition. Certain regions of CYP2A6 became more rigid due to variations, which could have a negative impact on the catalytic activity, regulatory interactions, and general function of the enzyme in metabolism. Globally the variations did not cause large changes to the protein, there is need for a local analysis using Dynamic Residue Networks to study how residue interactions affect the function of CYP2A6. , Thesis (MSc) -- Faculty of Science, Biochemistry, Microbiology and Bioinformatics, 2025
- Full Text:
- Date Issued: 2025-04-02
Evaluating metabolism-induced toxicity using a non-hepatic cell line
- Authors: Weyers, Carli
- Date: 2018
- Subjects: Cytochrome P-450 , Drugs Metabolism , Drugs Design
- Language: English
- Type: Master's theses , text
- Identifier: http://hdl.handle.net/10962/61950 , vital:28087
- Description: The drug discovery pipeline is a complicated process taking roughly 15 years to complete, costing in excess of $1 billion per new chemical entity. It has been estimated that for every 100, 000 promising hit or lead compounds, only one will make it onto the market due to numerous drug candidates being discarded because of many complications. One such complication is metabolism-induced toxicity. Accordingly, an early understanding of the metabolism of any new chemical entity is becoming an integral part of the pipeline. In order to explore this, various methods have been developed including in silico and in vitro techniques. One such method involves performing cell viability assays on human liver cancer cell lines, which overexpress specific metabolic cytochrome P450 enzymes. If a toxic metabolite is produced it would result in reduced cell viability of the transformed cell line in comparison to a control. Since the liver is the primary site of metabolism in the human body, we were curious as to the extent to which background metabolism may play a role in the degree to which toxic metabolites would be produced in these cell lines. The aim of this project, therefore, was to establish if a non-hepatic cell-based system which overexpresses CYP3A4 could be used to detect the metabolism and any subsequent toxicity of compounds which have been reported to be substrates of the CYP450 enzyme. The HEK293 cell line was stably transfected with a plasmid vector for human CYP3A4 to create a model overexpression system for our metabolism studies. The activity of the enzyme was confirmed using the substrate, 7-benzyloxy-4-trifluoromethyl-coumarin. Subsequently, cytotoxicity testing was done on four known pharmaceuticals reported to generate toxic metabolites in hepatic cell-based assays. In silico metabolic predictions on the four known compounds were performed and compared to the results of published literature. Finally, the metabolism of one compound was studied using a combination of high performance liquid chromatography (HPLC) and liquid chromatography-mass spectrometry (LC-MS) in order to detect predicted metabolites. We observed no change in cellular toxicity nor did we detect the formation of metabolites, even though the overexpressed CYP3A4 enzyme was active. The results suggest that caution should be taken when interpreting the results of cell-based metabolism studies, and background metabolism may play a significant role in the data. , Thesis (MSc) -- Faculty of Pharmacy, Pharmacy, 2018
- Full Text:
- Date Issued: 2018
- Authors: Weyers, Carli
- Date: 2018
- Subjects: Cytochrome P-450 , Drugs Metabolism , Drugs Design
- Language: English
- Type: Master's theses , text
- Identifier: http://hdl.handle.net/10962/61950 , vital:28087
- Description: The drug discovery pipeline is a complicated process taking roughly 15 years to complete, costing in excess of $1 billion per new chemical entity. It has been estimated that for every 100, 000 promising hit or lead compounds, only one will make it onto the market due to numerous drug candidates being discarded because of many complications. One such complication is metabolism-induced toxicity. Accordingly, an early understanding of the metabolism of any new chemical entity is becoming an integral part of the pipeline. In order to explore this, various methods have been developed including in silico and in vitro techniques. One such method involves performing cell viability assays on human liver cancer cell lines, which overexpress specific metabolic cytochrome P450 enzymes. If a toxic metabolite is produced it would result in reduced cell viability of the transformed cell line in comparison to a control. Since the liver is the primary site of metabolism in the human body, we were curious as to the extent to which background metabolism may play a role in the degree to which toxic metabolites would be produced in these cell lines. The aim of this project, therefore, was to establish if a non-hepatic cell-based system which overexpresses CYP3A4 could be used to detect the metabolism and any subsequent toxicity of compounds which have been reported to be substrates of the CYP450 enzyme. The HEK293 cell line was stably transfected with a plasmid vector for human CYP3A4 to create a model overexpression system for our metabolism studies. The activity of the enzyme was confirmed using the substrate, 7-benzyloxy-4-trifluoromethyl-coumarin. Subsequently, cytotoxicity testing was done on four known pharmaceuticals reported to generate toxic metabolites in hepatic cell-based assays. In silico metabolic predictions on the four known compounds were performed and compared to the results of published literature. Finally, the metabolism of one compound was studied using a combination of high performance liquid chromatography (HPLC) and liquid chromatography-mass spectrometry (LC-MS) in order to detect predicted metabolites. We observed no change in cellular toxicity nor did we detect the formation of metabolites, even though the overexpressed CYP3A4 enzyme was active. The results suggest that caution should be taken when interpreting the results of cell-based metabolism studies, and background metabolism may play a significant role in the data. , Thesis (MSc) -- Faculty of Pharmacy, Pharmacy, 2018
- Full Text:
- Date Issued: 2018
- «
- ‹
- 1
- ›
- »